High-risk prostate cancer treated with a stereotactic body radiation therapy boost following pelvic nodal irradiation.

Publication Year: 2024

DOI:
10.3389/fonc.2024.1325200

PMCID:
PMC10895712

PMID:
38410097

Journal Information

Full Title: Front Oncol

Abbreviation: Front Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest Author JL is a paid speaker for Accuray. JH is an Accuray consultant. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision."

Evidence found in paper:

"The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025